BenchSci is a life sciences AI healthcare company driving innovation in preclinical research. It leverages advanced artificial intelligence to accelerate scientific discovery, improve experimental outcomes, and streamline drug discovery by integrating biological data, domain expertise, and research insights, supporting scientists in making faster, more informed decisions.
BenchSci operates as an artificial intelligence healthcare specialist which works to enhance biomedical research and speed up pharmaceutical development. The platform uses artificial intelligence together with data analytics to assist researchers in making better research decisions at a faster pace while achieving operational efficiency and research success.
The company partners with pharmaceutical firms and research institutions worldwide, providing innovative solutions that streamline discovery processes using clinical data integration solutions. The organization has received acknowledgment for building a collaborative environment that supports scientific excellence while delivering major advancements to healthcare.
| Legal Name | Scinapsis Analytics Inc |
| Headquarters | Toronto, Ontario, Canada |
| Business Model | B2B |
| Founding Date | 2015 |
| No. of Employees | Approx 292 (As of 2025) |
BenchSci provides solutions including the ASCEND neuro-symbolic AI platform, Biological Evidence Knowledge Graph (BEKG), AI co-scientists and copilots, multi-omics and clinical data integration, proprietary internal data mapping, scientific curation and validation, deployment and change management services, and comprehensive AI-driven preclinical research and drug discovery solutions.
| Liran Belenzon | Chief Executive Officer |
| Tom Leung | Chief Science Officer |
| Elvis Wianda, Ph.D. | Chief Data Officer |
| Peter Grandsard | SVP, Strategy |
| Casandra Mangroo | SVP, Strategic Alliances |
| Chad Malek | Chief Commercial Officer |
| Nika Stelman | VP, Talent |
| John Jackson | Chief Technology Officer |
| Bryn Knox | Chief Financial Officer |
| Brian Smith | SVP, Account Services & Delivery |
BenchSci generates revenue primarily through a SaaS model, charging pharmaceutical and biotech companies subscription or pay-per-use fees for access to its AI-powered ASCEND platform, while offering limited free access to academic and non profit researchers.
Client Segments: Pharmaceutical companies, biotech firms, and research organizations seeking to accelerate preclinical drug discovery and improve experimental success rates.
Target Organizations: Companies and institutions using AI-driven solutions for disease biology analysis, experimental design, reagent selection and R&D portfolio optimization through the ASCEND platform.
Target Geography: Global pharmaceutical and research organizations, academic and non-profit research centers worldwide.